Health groups lash out at HC order baning Biocon, Mylan from selling biosimilar breast cancer drug
Public health groups lashed out at High Court order that stopped Biocon, Mylan from selling biosimilar versions of breast cancer drug Herceptin.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Breast Cancer | Cancer | Cancer & Oncology | Health | Herceptin | International Medicine & Public Health | Legislation | Pharmaceuticals